133 related articles for article (PubMed ID: 33603144)
1. Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations.
Awada H; Kerr CM; Durmaz A; Adema V; Gurnari C; Pagliuca S; Zawit M; Kongkiatkamon S; Rogers HJ; Saunthararajah Y; Sekeres MA; Carraway H; Maciejewski JP; Visconte V
Leukemia; 2021 Nov; 35(11):3324-3328. PubMed ID: 33603144
[No Abstract] [Full Text] [Related]
2. SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
van der Werf I; Wojtuszkiewicz A; Yao H; Sciarrillo R; Meggendorfer M; Hutter S; Walter W; Janssen J; Kern W; Haferlach C; Haferlach T; Jansen G; Kaspers GJL; Groen R; Ossenkoppele G; Cloos J
Leukemia; 2021 Sep; 35(9):2698-2702. PubMed ID: 34002025
[No Abstract] [Full Text] [Related]
3. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.
Boiocchi L; Hasserjian RP; Pozdnyakova O; Wong WJ; Lennerz JK; Le LP; Dias-Santagata D; Iafrate AJ; Hobbs GS; Nardi V
Hum Pathol; 2019 Apr; 86():1-11. PubMed ID: 30594750
[TBL] [Abstract][Full Text] [Related]
4. Co-mutation of
Song J; Moscinski L; Yang E; Shao H; Hussaini M; Zhang H
In Vivo; 2023; 37(3):985-993. PubMed ID: 37103105
[TBL] [Abstract][Full Text] [Related]
5. Clonal shifts in MDS - from SF3B1 to EZH2.
Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
[No Abstract] [Full Text] [Related]
6. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
7. Does
Song J; Moscinski L; Zhang H; Zhang X; Hussaini M
Cancer Genomics Proteomics; 2019; 16(1):91-98. PubMed ID: 30587503
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
9. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
10. Altered DNA Methylation Profiles in
Pacholewska A; Grimm C; Herling CD; Lienhard M; Königs A; Timmermann B; Altmüller J; Mücke O; Reinhardt HC; Plass C; Herwig R; Hallek M; Schweiger MR
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502260
[TBL] [Abstract][Full Text] [Related]
11. The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome.
Rujirachaivej P; Siriboonpiputtana T; Rerkamnuaychoke B; Magmuang S; Chareonsirisuthigul T; Boonsakan P; Petvises S; Sirirat T; Niparuck P; Chuncharunee S
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1825-1831. PubMed ID: 30049194
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
14. Somatic
Foy A; McMullin MF
J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
16. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
18. Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?
Todisco G; Moura PL; Hellström-Lindberg E
Semin Hematol; 2022 Jul; 59(3):150-155. PubMed ID: 36115692
[TBL] [Abstract][Full Text] [Related]
19. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic Syndrome Updated.
Hasserjian RP
Pathobiology; 2019; 86(1):7-13. PubMed ID: 30041243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
